These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22859930)

  • 1. The role of surfactant in respiratory distress syndrome.
    Ma CC; Ma S
    Open Respir Med J; 2012; 6():44-53. PubMed ID: 22859930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
    Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future.
    Jeon GW
    Korean J Pediatr; 2019 May; 62(5):155-161. PubMed ID: 30744318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll R; Wiswell TE
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006180. PubMed ID: 19821357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized controlled, non-inferiority trial, comparing nasal continuous positive airway pressure with nasal intermittent positive pressure ventilation as primary support before minimally invasive surfactant administration for preterm infants with respiratory distress syndrome (the NIV-MISA-RDS trial): Study protocol.
    Zhang H; Li J; Zeng L; Gao Y; Zhao W; Han T; Tong X
    Front Pediatr; 2022; 10():968462. PubMed ID: 35967549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
    Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
    Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.
    Stevens TP; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2002; (2):CD003063. PubMed ID: 12076469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
    Stevens TP; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2004; (3):CD003063. PubMed ID: 15266470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD006069. PubMed ID: 17943881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lucinactant for the treatment of respiratory distress syndrome in neonates.
    Piehl E; Fernandez-Bustamante A
    Drugs Today (Barc); 2012 Sep; 48(9):587-93. PubMed ID: 23032799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surfactant therapy: the current practice and the future trends.
    Altirkawi K
    Sudan J Paediatr; 2013; 13(1):11-22. PubMed ID: 27493353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
    Ardell S; Pfister RH; Soll R
    Cochrane Database Syst Rev; 2015 May; (5):CD000144. PubMed ID: 26009996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative pharmacoeconomic assessment of two surfactants for the prevention of respiratory distress syndrome.
    Gdovin JM; Moya F; Vishalpura T; Grogg A
    J Pediatr Pharmacol Ther; 2006 Jan; 11(1):43-54. PubMed ID: 23118645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exogenous surfactant therapy: new synthetic surfactants].
    Lacaze-Masmonteil T
    Arch Pediatr; 2008 Jun; 15 Suppl 1():S42-6. PubMed ID: 18822258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant respiratory therapy using Surfaxin/sinapultide.
    Lal MK; Sinha SK
    Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing a right surfactant for respiratory distress syndrome treatment.
    Ramanathan R
    Neonatology; 2009; 95(1):1-5. PubMed ID: 18832858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
    Rojas-Reyes MX; Morley CJ; Soll R
    Cochrane Database Syst Rev; 2012 Mar; (3):CD000510. PubMed ID: 22419276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.